DK1713471T3 - Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme - Google Patents

Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme

Info

Publication number
DK1713471T3
DK1713471T3 DK05701141.3T DK05701141T DK1713471T3 DK 1713471 T3 DK1713471 T3 DK 1713471T3 DK 05701141 T DK05701141 T DK 05701141T DK 1713471 T3 DK1713471 T3 DK 1713471T3
Authority
DK
Denmark
Prior art keywords
combination
respiratory diseases
inhaled
anticholinergics
inhibitors
Prior art date
Application number
DK05701141.3T
Other languages
English (en)
Inventor
Joachim Maus
Peter Juergen Cnota
Istvan Szelenyi
Beatrix Fyrnys
Original Assignee
Meda Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co Kg filed Critical Meda Pharma Gmbh & Co Kg
Application granted granted Critical
Publication of DK1713471T3 publication Critical patent/DK1713471T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05701141.3T 2004-02-06 2005-01-24 Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme DK1713471T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195504P 2004-02-06 2004-02-06
PCT/EP2005/000651 WO2005074982A2 (en) 2004-02-06 2005-01-24 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
DK1713471T3 true DK1713471T3 (da) 2012-05-14

Family

ID=34837532

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05701141.3T DK1713471T3 (da) 2004-02-06 2005-01-24 Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme

Country Status (19)

Country Link
US (3) US20050175547A1 (da)
EP (1) EP1713471B1 (da)
JP (1) JP4700014B2 (da)
CN (2) CN100512813C (da)
AT (1) ATE541570T1 (da)
AU (1) AU2005210084B2 (da)
CA (1) CA2550848C (da)
CY (1) CY1112968T1 (da)
DK (1) DK1713471T3 (da)
ES (1) ES2381116T3 (da)
HK (1) HK1096311A1 (da)
HR (1) HRP20120286T1 (da)
NO (1) NO337023B1 (da)
NZ (1) NZ548301A (da)
PL (1) PL1713471T3 (da)
PT (1) PT1713471E (da)
RU (1) RU2437658C2 (da)
SI (1) SI1713471T1 (da)
WO (1) WO2005074982A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1720543A1 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Roflumilast and glycopryrronium combination
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CA2626612A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
JP2011500731A (ja) * 2007-10-25 2011-01-06 メルク フロスト カナダ リミテツド 併用療法
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
PL2948148T3 (pl) * 2013-01-28 2021-01-25 Incozen Therapeutics Pvt. Ltd. Sposoby leczenia zaburzeń autoimmunologicznych, oddechowych i zapalnych przez wziewne podawanie n-tlenku roflumilastu
AU2014229739B2 (en) * 2013-03-15 2018-07-26 Verona Pharma Plc Drug combination
TW201542207A (zh) * 2013-10-03 2015-11-16 Otsuka Pharma Co Ltd 嚴重氣喘治療劑
CN104586841A (zh) * 2013-10-30 2015-05-06 中国药科大学 (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000043I1 (de) * 1993-07-02 2011-01-27 Nycomed Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) * 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
PT1131059E (pt) * 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040028958A1 (en) * 2002-06-18 2004-02-12 Total Innovative Manufacturing Llc Recyclable fire-resistant moldable batt and panels formed therefrom
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
SK286394B6 (sk) 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL158776A0 (en) * 2001-05-25 2004-05-12 Pfizer A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ATE347361T1 (de) * 2001-05-25 2006-12-15 Boehringer Ingelheim Pharma Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
CA2519682A1 (en) 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
WO2004084896A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
US20060155491A1 (en) 2003-07-11 2006-07-13 Peter Bode Frequency determination

Also Published As

Publication number Publication date
NO337023B1 (no) 2015-12-28
US8097605B2 (en) 2012-01-17
JP4700014B2 (ja) 2011-06-15
AU2005210084A1 (en) 2005-08-18
HRP20120286T1 (hr) 2012-04-30
RU2437658C2 (ru) 2011-12-27
US20050175547A1 (en) 2005-08-11
ES2381116T3 (es) 2012-05-23
NO20063880L (no) 2006-11-02
RU2006132040A (ru) 2008-03-20
ATE541570T1 (de) 2012-02-15
EP1713471B1 (en) 2012-01-18
CA2550848A1 (en) 2005-08-18
HK1096311A1 (en) 2007-06-01
CN1909899A (zh) 2007-02-07
CN100512813C (zh) 2009-07-15
PL1713471T3 (pl) 2012-06-29
WO2005074982A2 (en) 2005-08-18
WO2005074982A3 (en) 2006-04-06
EP1713471A2 (en) 2006-10-25
CA2550848C (en) 2013-02-26
US20060251589A1 (en) 2006-11-09
NZ548301A (en) 2010-07-30
CN101518532A (zh) 2009-09-02
JP2007520507A (ja) 2007-07-26
SI1713471T1 (sl) 2012-07-31
PT1713471E (pt) 2012-04-10
CY1112968T1 (el) 2016-04-13
US20090136429A1 (en) 2009-05-28
AU2005210084B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
DK1713471T3 (da) Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme
NO20075287L (no) Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser
WO2007071313A3 (en) Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
MXPA02011311A (es) Composicion novedosa.
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20070588L (no) Piperidinderivater som NK1-antagonister.
WO2006117299A3 (en) Novel crystalline forms of tiotropium bromide
MY140021A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2010038085A3 (en) P38 map kinase inhibitors
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
SE0200356D0 (sv) Novel use
WO2004062603A3 (en) Methods of treating lung diseases
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
MXPA03010162A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
HRP20140073T1 (hr) Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
EA200100906A1 (ru) Композиция контролируемого высвобождения для лечения copd хронического обструктивного заболевания легких
NO20084564L (no) Stramme "Constrained" forbindelser som CGRP-reseptor antagonister
TW200610529A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith